In gastrointestinal malignancies, autoantibodies against p53 and NY-ESO-1 track with tumor progression – particularly in esophageal squamous-cell carcinoma and gastric cancer – underscoring their prognostic potential [16]. This evidence concerns the gene TP53 and gastric cancer.